Skip to content
New: 30 more Indian companies explained, from Ather and Pine Labs to IDBI Bank

Healthcare · NSE: ZYDUSLIFE · BSE: 532321

Zydus Lifesciences: how the business works

Zydus Lifesciences makes generic medicines for the US and branded medicines for India, and earned ₹27,148 crore of revenue in FY26.

Follow Zydus Lifesciences

Email me when Zydus Lifesciences's page is updated after results.

We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.

Zydus Lifesciences Limited · Ahmedabad, Gujarat · Founded 1995

Updated for Q2 FY27 · checked

Revenue, FY26
₹27,148 cr
Profit to shareholders, FY26 (restated)
₹5,095 cr
Manufacturing facilities
44
Employees (group, approx.)
30,000
Promoter holding, 30 Sep 2026
75.01%

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

The short version

Zydus Lifesciences in 5 points

  1. 1 · What it sells

    Zydus Lifesciences makes generic medicines for the US, branded medicines for India, consumer health products and orthopaedic implants, and its FY26 revenue from operations was ₹27,148 crore.

    More: what it sells

  2. 2 · Who pays it

    In FY26, buyers in the US paid 43.2% of Zydus's revenue, buyers in India 35.8%, Europe 9.9% and other countries 11.2%.

    More: who pays it

  3. 3 · What it keeps from ₹100

    Of every ₹100 that came in during FY26, Zydus kept ₹18.4 as profit after ₹1.9 of one-off charges and with ₹4.6 of currency gains counted against costs, and its profit before one-off items, joint-venture share and tax was ₹7,203 crore.

    More: what it keeps from ₹100

  4. 4 · Where the operating profit comes from

    Pharmaceuticals earned ₹7,049 crore of segment profit before one-off items and tax in FY26, consumer products ₹267 crore, and medical technologies lost ₹113 crore.

    More: where the operating profit comes from

  5. 5 · The one thing to watch

    Net debt (Cityfort calculation) went from net cash of ₹4,643 crore on 31 Mar 2025 to ₹8,034 crore on 30 Sep 2026, and the company put its net debt at 0.62 times EBITDA on its own measure.

    More: the one thing to watch

Sources: From Zydus Lifesciences' FY26 annual report, its Q2 FY27 results and press release, and its 4 Nov 2026 earnings call · checked

01Where the money goes · FY26

Where does ₹100 of Zydus Lifesciences' money go?

Of every ₹100 that came in (revenue plus other income), this is where it went.

Zydus Lifesciences · FY26

Receipt for every ₹100

Where ₹100 of Zydus Lifesciences' money went in FY26
Materials and goods bought₹26.4
Employees₹16.0
Other running costs (after currency gains)₹25.2
Depreciation and amortisation₹4.9
One-off charges₹1.9
Interest, tax and minority owners' share, less joint-venture profit₹7.3
Kept as profit for shareholders₹18.4
Total₹100

Each line = amount ÷ total money in × 100. Lines may not add to exactly ₹100 because of rounding.

How this is worked out

Of every ₹100 that came in (revenue ₹27,148 crore + other income ₹510 crore), from the money flow above; each line ÷ ₹27,658 crore × 100 (Cityfort calculation).

Save this receipt as an image

Embed this receipt or the key numbers

Paste this code into a blog or website to show the card you choose, with a link back to this page.

Each week: the next company due to report results, explained in 5 points.

We'll email you once a week with what changed on Cityfort. Facts only, no tips. Unsubscribe any time.

We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.

02The business in one line

What does Zydus Lifesciences do?

Wholesalers, distributors and hospitals in the US, India and other countries pay Zydus for its medicines and health products; most of the money goes on materials, staff and running costs such as research, and ₹18.4 of every ₹100 was left as profit in FY26.

  • In FY26 buyers in the US paid 43.2% of Zydus's revenue and buyers in India 35.8%; one customer, not named, paid 12.4%.
  • Of every ₹100 that came in during FY26, ₹26.4 went on materials, ₹16.0 on staff and ₹25.2 on other running costs, after currency gains.

03Who pays it

Who pays Zydus Lifesciences?

  • Buyers in the US

    43.2%

    of revenue

    Generic and specialty medicines. One US-based wholesaler owed more than 10% of Zydus's trade receivables on 31 Mar 2026. Share is of FY26 revenue by customer location.

  • Buyers in India

    35.8%

    of revenue

    Branded medicines reach patients through a distributor network and chemists, and hospitals buy directly. India also buys Zydus Wellness consumer products.

  • Buyers in Europe

    9.9%

    of revenue

    Rose from ₹402 crore in FY25 to ₹2,675 crore in FY26, the first year with Amplitude (France) and Comfort Click (UK) in the accounts.

  • Buyers in other countries

    11.2%

    of revenue

    Medicines sold in other markets through subsidiaries and distributors.

  • Buyers in the US43.2%
  • Buyers in India35.8%
  • Buyers in Europe9.9%
  • Buyers in other countries11.2%

Customer concentration

One customer, not named, paid ₹3,364 crore, 12.4% of FY26 revenue (Cityfort calculation from the segment note). A single customer also passed 10% in FY23 (13.3%) and FY24 (11.2%), but not in FY22 or FY25.

Largest customer
12%

04How it makes money

How does Zydus Lifesciences make money?

Medicines cost little in materials; prices, new launches and approved plants shape the profit.

Materials cost ₹26.9 per ₹100 of revenue in FY26, down from ₹36.7 in FY22. Most costs are staff and other running costs, which include ₹2,273 crore of research. CRISIL's Dec 2024 report noted price erosion in US generics, and Zydus launched 5 new US products in Q2 FY27.

Materials cost per ₹100 of revenue

₹36.7₹26.9

FY22 to FY26

  1. Scientists develop generics and new drugs: R&D was ₹2,273 crore, 8.4% of FY26 revenue.
  2. Zydus files for approval: 4 US generic applications and 12 approvals in Q2 FY27.
  3. 44 plants make the medicines; US sales need plants that pass USFDA inspections.
  4. US wholesalers, India's distributors and hospitals buy them; doctors prescribe the India brands.
  5. US generic prices erode over time (CRISIL, Dec 2024), and new launches add sales: 5 in Q2 FY27.
  6. Cash from sales pays for more research and for purchases such as Assertio.

↺ Step 6 feeds back into step 1.

05Business segments · FY26

Which businesses make up Zydus Lifesciences?

  • Pharmaceuticals

    82.6%

    Medicines and drug ingredients worldwide: US generics and specialty drugs, India brands, other countries and APIs. Profit shown is the segment result before one-off items and tax; the three segment results add up to ₹7,203 crore.

    Revenue ₹22,412 cr · Operating profit ₹7,049 cr

  • Consumer products

    14.6%

    Zydus Wellness (57.59% owned), including Comfort Click of the UK from 29 Aug 2025.

    Revenue ₹3,954 cr · Operating profit ₹267 cr

  • Medical technologies

    2.9%

    Amplitude Surgical's implants, a new segment from FY26 (loss restated to ₹113 crore from ₹178 crore). Earlier years had two segments, so the history shows only FY25 and FY26 on the three-segment basis.

    Revenue ₹782 cr · Operating profit −₹113 cr

How the mix changed

  • Pharmaceuticals
  • Consumer products
  • Medical technologies

Revenue by segment, FY25 to FY26.

₹ crore

See the numbers
How the mix changed (₹ crore)
YearPharmaceuticalsConsumer productsMedical technologies
FY25₹20,542₹2,698₹2.4
FY26₹22,412₹3,954₹782

06The numbers · Consolidated · ₹ crore

How has Zydus Lifesciences done?

Revenue

₹27,148 crFY26

Revenue rose every year, from ₹15,110 crore in FY22 to ₹27,148 crore in FY26, and Q2 FY27 revenue of ₹7,910 crore was 29.2% higher than in Q2 FY26.

₹ crore

See the numbers
Revenue (₹ crore)
PeriodRevenue (₹ cr)
FY22₹15,110
FY23₹17,237
FY24₹19,547
FY25₹23,242
FY26₹27,148
Q3 FY25₹5,269
Q4 FY25₹6,528
Q1 FY26₹6,574
Q2 FY26₹6,123
Q3 FY26₹6,865
Q4 FY26₹7,587
Q1 FY27₹8,017
Q2 FY27₹7,910

Net profit

₹5,095 crFY26

Profit to shareholders rose from ₹1,960 crore in FY23, a year with ₹604 crore of one-off charges, to ₹5,095 crore in FY26 (restated), while FY22's ₹4,487 crore included ₹2,246 crore from the animal-health business sold in 2021. In the quarters, Q4 FY25 and Q4 FY26 carry one-off charges of ₹220 crore and ₹398 crore, Q2 FY26 and Q1 FY27 are restated, and Q3 and Q4 FY26 are as first filed; restated figures for them were not published.

₹ crore

See the numbers
Net profit (₹ crore)
PeriodNet profit (₹ cr)EPS (₹)
FY22₹4,487₹43.83
FY23₹1,960₹19.30
FY24₹3,860₹38.14
FY25₹4,526₹44.97
FY26₹5,095₹50.63
Q3 FY25₹1,024₹10.17
Q4 FY25₹1,171₹11.64
Q1 FY26₹1,467₹14.58
Q2 FY26₹1,261₹12.53
Q3 FY26₹1,042₹10.36
Q4 FY26₹1,273₹12.65
Q1 FY27₹960₹9.56
Q2 FY27₹926₹9.28

Net profit for every ₹100 of revenue

₹18.8FY26

Zydus kept ₹18.8 to ₹19.7 of profit per ₹100 of revenue from FY24 to FY26, against ₹11.4 in FY23 and ₹29.7 in FY22, the year of the animal-health sale. The table's EBITDA margin is a Cityfort calculation on reported profit before tax: 29.7% in FY26, which includes ₹1,280 crore of currency gains and is after ₹517 crore of one-off charges. In Q2 FY27 it was 24.3%, against the company's own EBITDA margin of 24.0%.

Net margin: ₹ of net profit per ₹100 of revenue

See the numbers
Net profit for every ₹100 of revenue (Net margin: ₹ of net profit per ₹100 of revenue)
YearNet marginEBITDA margin
FY2229.7%23.2%
FY2311.4%19.4%
FY2419.7%28.1%
FY2519.5%29.7%
FY2618.8%29.7%

Free cash flow

−₹555 crFY26

Cash from operations fell from ₹6,781 crore in FY25 to ₹2,117 crore in FY26, with a ₹2,624 crore working-capital outflow and a ₹1,753 crore currency adjustment. Capital spending rose to ₹2,672 crore, so free cash flow was −₹555 crore, before ₹6,602 crore spent on acquisitions.

₹ crore · cash from operations minus spending on plants and equipment

See the numbers
Free cash flow (₹ crore · cash from operations minus spending on plants and equipment)
YearCash from operationsCapital spendingFree cash flow
FY22₹2,105₹1,203₹902
FY23₹2,689₹1,031₹1,658
FY24₹3,196₹907₹2,290
FY25₹6,781₹1,694₹5,087
FY26₹2,117₹2,672−₹555
See all yearly numbers
Zydus Lifesciences annual financials, FY22–FY26, ₹ crore
YearRevenueEBITDANet profitEPS (₹)Operating cashCapexFree cash
FY22₹15,110₹3,500₹4,487₹43.83₹2,105₹1,203₹902
FY23₹17,237₹3,350₹1,960₹19.30₹2,689₹1,031₹1,658
FY24₹19,547₹5,489₹3,860₹38.14₹3,196₹907₹2,290
FY25₹23,242₹6,897₹4,526₹44.97₹6,781₹1,694₹5,087
FY26 (restated)₹27,148₹8,056₹5,095₹50.63₹2,117₹2,672−₹555

EBITDA = profit before interest, tax and wear-and-tear of assets. Financial year runs April to March (March year end). Net profit is the share belonging to the company's owners.

07Who runs it

Who runs Zydus Lifesciences, and did they deliver?

  • Pankaj R. Patel

    Chairman

    Promoter; son of founder Ramanbhai Patel, per CRISIL.

  • Dr Sharvil P. Patel

    Managing Director

    Third-generation promoter, per CRISIL.

  • Ganesh N. Nayak

    Director

    Board member.

  • Tushar D. Shroff

    Chief Financial Officer · since 2025

    From 1 Sep 2025, after Nitin Parekh.

  • Dhaval N. Soni

    Company Secretary

What they said, and what happened

1 delivered · 3 too early to tell

  1. Said on 10 Feb 2026

    Management said on the Q3 FY26 call that Zydus would still reach an EBITDA margin above 23% in Q4 FY26, even with very little or no lenalidomide sales.

    What happened

    The company's own EBITDA margin was 33.7% in Q4 FY26, including ₹645 crore of currency gains; Cityfort's calculation on reported profit before tax gives 28.4%.

    Delivered
  2. Said on 19 May 2026

    Dr Sharvil Patel said on the Q4 FY26 call that Zydus expected "high teens growth" in FY27 consolidated revenue; on 11 Aug 2026 he said it would deliver strong double-digit growth for the year.

    What happened

    H1 FY27 revenue was ₹15,927 crore, 25.4% more than in H1 FY26.

    Too early to tell
  3. Said on 19 May 2026

    Dr Sharvil Patel said on the same call that the FY27 EBITDA margin was expected to be above 24%; on 4 Nov 2026 he said Zydus was on track for a 24% plus margin.

    What happened

    The company's own EBITDA margin was 24.0% in H1 FY27; Cityfort's calculation on reported profit before tax gives 24.3%.

    Too early to tell
  4. Said on 19 May 2026

    Management said on 19 May 2026 that FY27 capital spending would be around ₹1,500 crore, with quarterly depreciation around ₹550 crore.

    What happened

    Organic capital spending was ₹1,053 crore in H1 FY27, and depreciation was ₹605 crore in Q2 FY27.

    Too early to tell

08What could go wrong

What could go wrong for Zydus Lifesciences?

  • Pricing

    US generic prices and competition

    US buyers paid 43.2% of FY26 revenue. CRISIL's Dec 2024 report notes price erosion in US generics. When giving the FY27 margin outlook on 19 May 2026, Dr Sharvil Patel cited competition for lenalidomide and mirabegron and saroglitazar launch costs.

    Watch North America formulation sales each quarter: ₹3,315 crore in Q2 FY27.

  • Regulation

    USFDA plant inspections

    The Baddi plant received a USFDA warning letter on 3 Jun 2026. The Jarod injectables plant received one in Aug 2024, which the FY26 annual report says was resolved. US sales depend on plants passing these inspections.

    Watch Baddi remediation, and follow-up on the SEZ-II and Moraiya inspections, which closed with 1 and 5 observations.

  • Debt

    Debt after acquisitions

    Net debt (Cityfort calculation) went from net cash of ₹4,643 crore on 31 Mar 2025 to ₹8,034 crore on 30 Sep 2026. The company put net debt at 0.62 times EBITDA on its own measure on 30 Sep 2026. CRISIL reaffirmed AAA/Stable on 10 Sep 2026.

    Watch Net debt to EBITDA. Dr Sharvil Patel said on 4 Nov 2026 that Zydus is comfortable up to one times.

  • Execution

    Loss-making medical devices business

    The medical technologies segment lost ₹113 crore in FY26 (restated) and ₹150 crore in H1 FY27, before one-off items and tax. Goodwill and other intangible assets rose from ₹7,092 crore on 31 Mar 2025 to ₹15,822 crore on 30 Sep 2026.

    Watch The medical technologies segment result each quarter.

  • Cash and liquidity

    Weaker cash from operations in FY26

    Cash from operations fell from ₹6,781 crore in FY25 to ₹2,117 crore in FY26, with a ₹2,624 crore working-capital outflow and a ₹1,753 crore currency adjustment on consolidation. Free cash flow was −₹555 crore.

    Watch FY27 cash from operations. Inventories were ₹6,882 crore on 30 Sep 2026, up from ₹5,628 crore on 31 Mar 2026.

  • Legal

    US lawsuits and settlements

    In US generic-drug pricing antitrust cases, plaintiffs alleged that many drug makers, including Zydus's US subsidiary, engaged in anti-competitive behaviour; it agreed on 5 Sep 2026 to pay US$5.9 million to indirect reseller plaintiffs, without any admission of fault or wrongdoing. In Feb 2026 Zydus agreed to pay Astellas US$120 million to end mirabegron patent litigation.

    Watch New settlements or provisions in the results notes.

  • Concentration

    One large customer

    One customer, not named, paid ₹3,364 crore, 12.4% of FY26 revenue. One US-based wholesaler owed more than 10% of trade receivables on 31 Mar 2026.

    Watch The large-customer line in the FY27 segment note.

09Supporters and critics

What do supporters and critics point to?

Facts each side points to. We don't say which side is right.

What supporters point to

  • Revenue rose every year from FY22 to FY26, to ₹27,148 crore, and H1 FY27 revenue was 25.4% higher than in H1 FY26.
  • India formulation sales rose 18.3% in Q2 FY27 to ₹1,884 crore, and international markets rose 33.2%.
  • Zydus says it was the third-largest generics company in the US by prescriptions (IQVIA, 12 months to Mar 2026).
  • Dr Sharvil Patel said branded products were about 57% of revenue in Q2 FY27, up 150 basis points from Q1.
  • CRISIL reaffirmed its AAA/Stable rating on 10 Sep 2026.

What critics point to

  • Q2 FY27 profit to shareholders was ₹926 crore, 26.6% less than in Q2 FY26, and the company's own EBITDA margin fell from 32.9% to 24.0%.
  • Net debt (Cityfort calculation) was ₹8,034 crore on 30 Sep 2026, against net cash of ₹4,643 crore on 31 Mar 2025.
  • Free cash flow was −₹555 crore in FY26, before ₹6,602 crore spent on acquisitions.
  • The medical technologies segment lost ₹150 crore in H1 FY27.
  • The USFDA issued a warning letter for the Baddi plant on 3 Jun 2026.

10What to watch next

What should you watch next at Zydus Lifesciences?

Next event

Q3 FY27 results

Date not announced yet.

  • US FDA date for saroglitazar

    The US FDA set 27 Nov 2026 as its target action date for Zydus's saroglitazar application in PBC, a liver disease (announced 27 May 2026). Dr Sharvil Patel said on 4 Nov 2026 that FY28 would bring no meaningful revenue from it.

  • Plant inspections

    Progress on the Baddi warning letter of 3 Jun 2026, and on the 1 and 5 USFDA observations at the SEZ-II and Moraiya plants.

  • Debt and margins

    Net debt was 0.62 times EBITDA on 30 Sep 2026 on the company's own measure. Dr Sharvil Patel said on 19 May and 4 Nov 2026 that Zydus expects an FY27 EBITDA margin above 24%; H1 FY27 was 24.0% on the company's measure.

11Key facts

Key facts about Zydus Lifesciences

What does Zydus Lifesciences do?
Zydus Lifesciences, based in Ahmedabad, makes generic medicines for the US, branded medicines prescribed by doctors in India and medicines for other countries. It also sells consumer health products through Zydus Wellness and orthopaedic implants through Amplitude Surgical of France.
How does Zydus Lifesciences make money?
Zydus Lifesciences earns most of its money selling medicines. Of its ₹26,720 crore of product sales in FY26, North America formulations were ₹11,682 crore, India formulations ₹6,574 crore, consumer wellness ₹3,913 crore and international markets ₹3,070 crore.
Who pays Zydus Lifesciences?
In FY26 buyers in the US paid 43.2% of Zydus Lifesciences' ₹27,148 crore revenue, buyers in India 35.8%, Europe 9.9% and other countries 11.2%. One customer, not named, paid 12.4% of FY26 revenue.
How big is Zydus Lifesciences?
Zydus Lifesciences reported FY26 revenue of ₹27,148 crore and profit to shareholders of ₹5,095 crore (as restated in its Q2 FY27 results). It has 44 manufacturing facilities and about 30,000 employees.
Who owns Zydus Lifesciences?
On 30 Sep 2026 the promoter group owned 75.01% of Zydus Lifesciences, Indian institutions 11.28%, foreign investors 7.05% and others 6.66%. The FY25 annual report shows most promoter shares held by Pankaj R. Patel as trustee of the Zydus Family Trust.
How much debt does Zydus Lifesciences have?
On 30 Sep 2026 Zydus Lifesciences had borrowings of ₹13,250 crore and cash and liquid investments of ₹5,216 crore, a net debt of ₹8,034 crore (Cityfort calculation). On 31 Mar 2025 it had ₹4,643 crore more cash than debt.
What has Zydus Lifesciences bought since 2025?
Zydus Lifesciences bought French orthopaedic-implant maker Amplitude Surgical for a total cost of €300 million (Jul–Oct 2025) and US company Assertio for about US$166.4 million (Jun 2026). Its subsidiary Zydus Wellness bought Comfort Click of the UK for £239 million in Aug 2025.
How did Zydus Lifesciences do in Q2 FY27?
In Q2 FY27 (Jul–Sep 2026) Zydus Lifesciences' revenue rose 29.2% from a year earlier to ₹7,910 crore, while profit to shareholders fell 26.6% to ₹926 crore.
What is Zydus Lifesciences' credit rating?
CRISIL rated Zydus Lifesciences' long-term bank facilities AAA with a Stable outlook and its short-term debt A1+, reaffirmed in letters dated 10 Sep 2026.

Terms on this page

Each explains the term in plain English, with the same number from other companies on Cityfort.

Go deeper

More detail from the same filings. Open any section.

12What it sells

12What it sells

What does Zydus Lifesciences sell?

Zydus makes medicines. In the US it mostly sells generics: cheaper copies of medicines whose patents have ended. In India it sells its own brands, which doctors prescribe. It also owns most of Zydus Wellness, a consumer health company, and since Jul 2025 a French maker of hip and knee implants.
  • North America formulations

    Generic and specialty medicines sold in the US and Canada. ₹11,682 crore of sales in FY26, 43.7% of product sales. Since Jun 2026 this includes Assertio's cancer-care biologic Rolvedon.

  • India formulations

    Branded medicines prescribed by doctors in India. ₹6,574 crore in FY26. Medicines for long-term (chronic and sub-chronic) conditions were 56.9% of the portfolio in the 12 months to Sep 2026 (AWACS).

  • Consumer wellness

    Zydus Wellness brands such as Glucon-D, Complan, Sugar Free, Nycil and Everyuth, plus UK online brands of Comfort Click from Aug 2025. ₹3,913 crore in FY26.

  • International markets formulations

    Medicines sold in other countries through subsidiaries and distributors. ₹3,070 crore in FY26.

  • MedTech

    Knee and hip implants from Amplitude Surgical, France, part of Zydus since 29 Jul 2025. ₹782 crore in FY26.

  • APIs and alliances

    Active pharmaceutical ingredients (the chemicals inside medicines) sold to other drug makers, plus partner income. ₹698 crore in FY26.

What it does

  • Does: Makes generic copies of off-patent medicines for the US market
  • Does: Sells its own medicine brands to doctors and chemists in India
  • Does: Develops its own new drugs, such as saroglitazar and desidustat
  • Does: Sells consumer health and food products through Zydus Wellness
  • Does: Makes knee and hip implants (prostheses) through Amplitude Surgical

What it does not do

  • Does not: Does not earn most of its revenue in India: US buyers paid 43.2% of FY26 revenue, India 35.8%
  • Does not: Does not own all of Zydus Wellness: it held 57.59% on 31 Mar 2026
  • Does not: Does not report profit by country: profit is shown only for its three business segments
13How the money flows

13How the money flows · FY26

How does money flow through Zydus Lifesciences?

Money in

  • Revenue from operations₹27,148 cr
  • Other income₹510 cr

The company

Zydus Lifesciences

₹27,658 cr came in

Money out

  • Materials and goods bought₹7,293 cr
  • Employees₹4,418 cr
  • Other running costs (after ₹1,280 cr of currency gains)₹6,963 cr
  • Depreciation and amortisation₹1,343 cr
  • One-off charges (mostly the Astellas settlement)₹517 cr
  • Interest, tax and minority owners' share, less joint-venture profit₹2,030 cr
  • Profit to Zydus shareholders₹5,095 cr
  1. In FY26 Zydus took in ₹27,148 crore from sales plus ₹510 crore of other income.
  2. Materials and goods bought cost ₹7,293 crore, ₹26.4 of every ₹100 that came in.
  3. Staff cost ₹4,418 crore. Other running costs were ₹6,963 crore after ₹1,280 crore of currency gains (₹4.6 per ₹100) counted against them.
  4. One-off charges took ₹517 crore (₹1.9 per ₹100), ₹398 crore of it the Astellas patent settlement.
  5. After depreciation, interest, tax and the share of minority owners, ₹5,095 crore was left for Zydus shareholders.
14What it needs to run

14What it needs to run

What does Zydus Lifesciences need to run?

  • Plants

    44 manufacturing facilities in FY26: 38 in India and 6 abroad. Plants selling to the US must pass USFDA inspections.

  • Research

    10 R&D centres and over 1,500 scientists. R&D spending was ₹2,273 crore in FY26, 8.4% of revenue.

  • Product approvals

    Each US generic needs an approved application (ANDA). In Q2 FY27 Zydus filed 4 and received 12 approvals, 2 of them tentative.

  • People

    29,980 permanent employees on 31 Mar 2026, and about 30,000 people in all.

15Where it sells

15Where it sells · FY26

Where does Zydus Lifesciences sell?

  • United States43.2%
  • India35.8%
  • Other countries11.2%
  • Europe9.9%
16Competitors and what protects it

16Competitors and what protects it

Who does Zydus Lifesciences compete with?

Zydus's own filings name no competitors. It says it was the third-largest generics company in the US by prescriptions (IQVIA, 12 months to Mar 2026). CRISIL's Dec 2024 report described intense competition from innovator companies and cost-competitive Indian makers. The rivals below sell the same kinds of medicines, per their own filings.
  • Sun Pharma

    NSE: SUNPHARMA

    Sells branded medicines in India and generic and specialty medicines in the US: India formulations ₹19,290 crore and US formulations ₹16,824 crore in FY26, per its results release.

  • Cipla

    NSE: CIPLA

    Sells branded medicines in India and generics in North America: One India ₹12,680 crore and North America ₹6,871 crore in FY26, per its results release.

  • Dr. Reddy's Laboratories

    NSE: DRREDDY

    Sells generics in North America and medicines in India: North America generics ₹11,374 crore and India ₹6,219 crore in FY26 (IFRS), per its results filing.

What protects the business

Each strength is scored 1 (weak) to 5 (strong) for the business, with the reason. It is not a rating of the share.

  • US generics reach4 of 5

    Zydus says it was the third-largest generics company in the US by prescriptions (IQVIA, 12 months to Mar 2026). North America formulation sales were ₹11,682 crore in FY26.

  • India brands3 of 5

    India formulation sales were ₹6,574 crore in FY26, against ₹19,290 crore for Sun Pharma and ₹12,680 crore for Cipla's One India business. Long-term-condition medicines were 56.9% of Zydus's India portfolio (AWACS, Sep 2026).

  • Research and own drugs3 of 5

    R&D was ₹2,273 crore, 8.4% of FY26 revenue, across 10 R&D centres. Its own new drugs include saroglitazar and desidustat.

  • Plants and approvals3 of 5

    44 manufacturing facilities. On 31 Mar 2026 none of its plants was under a warning letter, but the Baddi plant received one on 3 Jun 2026.

Weak spot

Reliance on US generics

US buyers paid 43.2% of FY26 revenue. CRISIL's Dec 2024 report noted price erosion in US generics, and management said in Feb 2026 it expected very little or no lenalidomide sales in Q4 FY26.

17Where growth could come from

17Where growth could come from

Where could Zydus Lifesciences' growth come from?

Managing Director Dr Sharvil Patel said on the Q4 FY26 call (19 May 2026) that Zydus expected "high teens growth" in FY27 consolidated revenue and an EBITDA margin above 24%. On 11 Aug 2026 he said it would deliver "strong double-digit growth" for the year, and on 4 Nov 2026 that it was on track for a 24% plus EBITDA margin.
Management statement, 19 May 2026. Reported as a statement, not our forecast.
  • Branded medicines in India

    Working

    India formulations +18.3%, Q2 FY27

    India formulation sales rose from ₹1,593 crore in Q2 FY26 to ₹1,884 crore in Q2 FY27, 24% of revenue. Branded sales grew 19%, the company said.

    Status: Working, on track against what the company said.

  • International markets

    Working

    +33.2%, Q2 FY27

    International markets formulation sales were ₹1,001 crore in Q2 FY27, up from ₹751 crore a year earlier, and ₹3,070 crore in FY26.

    Status: Working, on track against what the company said.

  • Consumer wellness

    Working

    +76.1%, Q2 FY27

    Sales were ₹1,122 crore in Q2 FY27, including Comfort Click (UK) from Aug 2025. The India business grew 29%, and the international business 12% on a like-for-like basis.

    Status: Working, on track against what the company said.

  • US specialty medicines

    New

    16% of US sales, Q2 FY27

    Zydus completed its purchase of Assertio, whose products include the cancer-care biologic Rolvedon, on 16 Jun 2026 for about US$166.4 million. The company said branded sales were 16% of its US business in Q2 FY27.

    Status: New, recently announced.

  • Saroglitazar in the US

    New

    FDA target date 27 Nov 2026

    The US FDA gave priority review to Zydus's application for saroglitazar, its own drug, in PBC, a liver disease, with a target action date of 27 Nov 2026. Dr Sharvil Patel said on 4 Nov 2026: "FY28 will not be any meaningful revenue."

    Status: New, recently announced.

  • Medical devices

    Early

    Segment loss ₹150 cr, H1 FY27

    Medical technologies revenue was ₹509 crore in H1 FY27, and the segment lost ₹150 crore before one-off items and tax.

    Status: Early, too early to judge.

Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.

18Financial strength and debt

18Financial strength · 30 Sep 2026

How much debt does Zydus Lifesciences have?

On 30 Sep 2026 Zydus's borrowings were ₹8,034 crore more than its cash and liquid investments; on 31 Mar 2025 its cash had been ₹4,643 crore more than its debt.
  • Total debt₹13,250 cr
  • Cash and investments₹5,216 cr
  • Net debt (debt minus cash)₹8,034 cr
  • Net worth (shareholders' money)₹27,817 cr
Debt to equity
0.48×
₹ of debt for every ₹1 of shareholders' money
  • Borrowings exclude lease liabilities (rent owed under leases) of ₹717 crore.
  • Cash and liquid investments = cash ₹669 crore + other bank balances ₹883 crore + current investments ₹3,664 crore. Non-current investments of ₹3,452 crore are not counted. Net debt is a Cityfort calculation.
  • Zydus's own measure, on a definition it does not disclose: net debt 0.19 times equity and 0.62 times EBITDA on 30 Sep 2026. Dr Sharvil Patel said on 4 Nov 2026 that net debt fell from ₹5,900 crore to ₹5,200 crore in the quarter.
  • Net debt (Cityfort calculation) was ₹4,577 crore on 31 Mar 2026. In FY26 Zydus took ₹7,071 crore of new long-term borrowings and spent ₹6,602 crore on acquisitions.
  • Goodwill and other intangible assets were ₹15,822 crore on 30 Sep 2026, against ₹7,092 crore on 31 Mar 2025 (Cityfort calculation: sum of the two lines).
  • Net worth is the equity belonging to Zydus shareholders. Minority owners, mainly of Zydus Wellness, held another ₹2,506 crore.
19Who owns it

19Who owns it · Q2 FY27

Who owns Zydus Lifesciences?

  • Promoters (founders or parent company)75.0%
  • Foreign institutions (FII)7.1%
  • Indian institutions (DII)11.3%
  • Public and others6.7%

Promoter pledge

No promoter shares were pledged in Q2 FY27.

How ownership changed
Zydus Lifesciences shareholding by quarter, %
QuarterPromotersFIIDIIPublicPledged*
Q3 FY2475.0%5.0%13.0%7.0%0.0%
Q4 FY2475.0%5.7%12.6%6.7%0.0%
Q1 FY2575.0%5.6%12.6%6.8%0.0%
Q2 FY2575.0%7.5%10.7%6.9%0.0%
Q3 FY2575.0%7.5%10.7%6.8%0.0%
Q4 FY2575.0%7.3%11.0%6.7%0.0%
Q1 FY2675.0%7.1%11.1%6.8%0.0%
Q2 FY2675.0%7.3%10.9%6.8%0.0%
Q3 FY2675.0%7.1%11.1%6.9%0.0%
Q4 FY2675.0%7.0%11.2%6.9%0.0%
Q1 FY2775.0%6.9%11.3%6.8%0.0%
Q2 FY2775.0%7.1%11.3%6.7%0.0%

* Pledged = share of the promoters' own holding reported as pledged. In older filings this can include shares “otherwise encumbered”; the governance flags say when.

20What it does with profit

20What it does with profit

What does Zydus Lifesciences do with its profit?

Dividend per share as declared for each year. Payout = dividend per share ÷ earnings per share (Cityfort calculation). The board recommended the FY26 dividend of ₹1 on 19 May 2026, the same day it approved the ₹1,100 crore buyback. Zydus paid ₹1,106 crore of dividends in FY26, for FY25.

Dividend per share

₹1.00FY26

Dividend paid for each share, by financial year.

₹ per share

See the numbers
Dividend per share (₹ per share)
YearDividend per shareShare of profit paid out
FY22₹2.505.7%
FY23₹6.0031.1%
FY24₹3.007.9%
FY25₹11.0024.5%
FY26₹1.002.0%
  • Buyback · 19 Jul 2022

    Bought back 11,538,461 shares at ₹650 each (₹750 crore); the FY24 annual report says the shares were extinguished on 19 Jul 2022. The FY23 cash flow shows ₹863 crore paid including tax and costs.

    ₹750 cr

  • Buyback · 15 Mar 2024

    Bought back 5,970,149 shares at ₹1,005 each (₹600 crore); the FY24 annual report says the shares were extinguished on 15 Mar 2024. The promoter's Zydus Family Trust received ₹387 crore.

    ₹600 cr

  • Buyback · 18 Jun 2026

    Tender-offer buyback approved by the board on 19 May 2026: 8,730,158 shares (0.87%) bought at ₹1,260, raised from ₹1,150 on 27 May 2026, and extinguished on 18 Jun 2026. ₹1,106 crore paid including expenses; the promoter holding was 75.01% afterwards.

    ₹1,100 cr

21Governance signals

21Governance signals

What do Zydus Lifesciences' governance filings show?

Auditor
Deloitte Haskins & Sells LLP
Auditor changes
4 Nov 2026: Deloitte Haskins & Sells LLP → Walker Chandiok & Co LLP (Mandatory rotation: Deloitte's second five-year term ends at the 32nd AGM, after the FY27 audit. The board approved Walker Chandiok from that AGM to the 37th AGM, subject to shareholder approval.)
Audit qualifications
None reported
Related-party dealings
This page does not summarise every related-party transaction. In FY24 Zydus paid ₹387 crore to the promoter's Zydus Family Trust for shares bought back from it, per the FY25 annual report. Zydus owned 57.59% of its subsidiary Zydus Wellness on 31 Mar 2026.
Credit rating
CRISIL AAA (long term), A1+ (short term) (outlook Stable), 10 Sep 2026

A credit rating describes the company's ability to repay debt. It is not a rating of the share.

Flags to know about

  • regulatory · 3 Jun 2026

    USFDA warning letter for the Baddi plant

    Received on 3 Jun 2026 after a records request under section 704(a)(4), not an on-site inspection. It references observations on the use of purified talc that did not meet current USP requirements. The company said it believes current operations and supplies from Baddi will not be affected.

  • other · 5 Sep 2026

    US generic-drug pricing antitrust cases

    Plaintiffs alleged that numerous drug makers, including Zydus Pharmaceuticals USA, engaged in anti-competitive behaviour. On 5 Sep 2026 the subsidiary agreed to pay US$5.9 million to settle with indirect reseller plaintiffs, without any admission of fault or wrongdoing.

  • disclosure · 4 Nov 2026

    Earlier quarters restated

    The Q2 FY27 results restated FY26, Q2 FY26 and Q1 FY27 after the Amplitude purchase-price allocation was finalised (FY26 profit to shareholders ₹5,040 crore → ₹5,095 crore). Restated Q3 and Q4 FY26 figures were not published.

  • pledge · 31 Dec 2025

    Tiny promoter pledge in Dec 2025

    A revised Dec 2025 shareholding filing shows 3,500 shares of one promoter-group member pledged, 0.0005% of the promoter holding. Filings from Mar 2026 show none.

22What the market paid

22What the market paid · price as of 11 Nov 2026

What did the market pay for Zydus Lifesciences on 11 Nov 2026?

Price as of 11 Nov 2026 (shown for education; prices change daily).

Price as of 11 Nov 2026: ₹1,199.50, the NSE closing price. Market value = price × 997,503,832 shares = ₹119,651 crore. P/E shows how many rupees the market price is for each rupee of yearly profit per share: price ÷ ₹42.36 earnings per share of the last four quarters (H1 FY27 ₹18.84 + FY26 ₹50.63 − H1 FY26 ₹27.11, restated) = 28.3. P/B = market value ÷ shareholders' equity on 30 Sep 2026 (₹27,817 crore) = 4.3. Dividend yield = FY26 dividend of ₹1 ÷ price = 0.08%. All are Cityfort calculations.

Share price
₹1,199.50
Market value (market cap)
₹119,651 cr
P/E
28.3×
P/B
4.3×

Source: NSE security-wise bhavcopy (sec_bhavdata_full), 11 Nov 2026: ZYDUSLIFE EQ close Rs 1,199.50; Shareholding pattern as of 30 Sep 2026; Q2 FY27 results (standalone and consolidated, with notes and balance sheet) and 1 more

23How it got here

23How it got here

How did Zydus Lifesciences get here?

  1. 1952

    Milestone

    Cadila Laboratories founded

    Ramanbhai Patel and Indravadan Modi set up Cadila Laboratories, the business Zydus grew from.

  2. 1995

    Business-model change

    Cadila Healthcare formed in the split

    Cadila Healthcare was incorporated in 1995 after Cadila Laboratories split. CRISIL says the Modi family's share moved to a new company and the division run by Pankaj Patel became Cadila Healthcare.

  3. 2021

    Business-model change

    Animal-health business sold

    Sold its India-focused animal-health business in Jul 2021. FY22 profit included ₹2,246 crore from these discontinued operations.

  4. 2022

    Milestone

    Renamed Zydus Lifesciences

    Cadila Healthcare became Zydus Lifesciences on 24 Feb 2022.

  5. 2024

    Crisis

    Warning letter for the Jarod plant

    Zydus received a USFDA warning letter for the Jarod injectables plant on 30 Aug 2024. The FY26 annual report says it was resolved.

  6. 2025

    Business-model change

    Into medical devices with Amplitude

    Bought 85.6% of Amplitude Surgical (France) on 29 Jul 2025 and the rest by Oct 2025, for €300 million in all. Medical technologies became a new segment.

  7. 2025

    Milestone

    Comfort Click bought

    Zydus Wellness bought UK online wellness company Comfort Click on 29 Aug 2025 for £239 million plus a £2.64 million profit ticker.

  8. 2026

    Milestone

    US biologics plants and Astellas settlement

    Bought Agenus's two California biologics plants for US$75 million upfront plus up to US$50 million later (15 Jan 2026). Signed a US$120 million settlement with Astellas on 10 Feb 2026 to end mirabegron patent litigation, disclosed on 12 Feb 2026.

  9. 2026

    Business-model change

    Assertio bought; Baddi warning letter

    Completed the US$166.4 million purchase of US specialty company Assertio on 16 Jun 2026. The Baddi plant received a USFDA warning letter on 3 Jun 2026.

24Sources and changes

Where every number on this page comes from

Sources (45 documents)
  1. S1Integrated Annual Report 2025-26 (FY26) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 30 Jun 2026
  2. S2Annual Report 2024-25 (FY25) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 3 Jul 2025
  3. S3Annual Report 2023-24 (FY24) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 12 Jul 2024
  4. S4Annual Report 2022-23 (FY23) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 18 May 2023
  5. S5Annual Report 2021-22 (FY22) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 15 Jul 2022
  6. S6Q2 FY27 results (standalone and consolidated, with notes and balance sheet) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 4 Nov 2026
  7. S8Q4 FY26 and FY26 audited results · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 19 May 2026
  8. S9Q3 FY26 results · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 9 Feb 2026
  9. S11Q1 FY26 results · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 12 Aug 2025
  10. S12Press release: financial performance for Q2 and H1 FY27 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 4 Nov 2026
  11. S14Press release: financial performance for Q4 and full year FY26 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 19 May 2026
  12. S21Q2 FY27 earnings call transcript (call 4 Nov 2026) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 7 Nov 2026
  13. S22Q1 FY27 earnings call transcript (call 11 Aug 2026) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 18 Aug 2026
  14. S23Q4 FY26 earnings call transcript (call 19 May 2026) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 24 May 2026
  15. S24Q3 FY26 earnings call transcript (call 10 Feb 2026) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 15 Feb 2026
  16. S25Shareholding pattern as of 31 Dec 2023 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 8 Jan 2024
  17. S26Shareholding pattern as of 31 Mar 2024 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 9 Apr 2024
  18. S27Shareholding pattern as of 30 Jun 2024 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 11 Jul 2024
  19. S28Shareholding pattern as of 30 Sep 2024 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 9 Oct 2024
  20. S29Shareholding pattern as of 31 Dec 2024 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 20 Jan 2025
  21. S30Shareholding pattern as of 31 Mar 2025 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 12 Apr 2025
  22. S31Shareholding pattern as of 30 Jun 2025 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 18 Jul 2025
  23. S32Shareholding pattern as of 30 Sep 2025 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 14 Oct 2025
  24. S33Shareholding pattern as of 31 Dec 2025 (revised) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 27 May 2026
  25. S34Shareholding pattern as of 31 Mar 2026 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 9 Apr 2026
  26. S35Shareholding pattern as of 18 Jun 2026 (post-buyback, Reg 31(1)(c)) · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 24 Jun 2026
  27. S36Shareholding pattern as of 30 Jun 2026 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 11 Jul 2026
  28. S37Shareholding pattern as of 30 Sep 2026 · Zydus Lifesciences Ltd (company IR site) · Tier 1: company or exchange filing · 7 Oct 2026
  29. S38Intimation of credit rating: CRISIL letters dated 10 Sep 2026 (AAA/Stable, A1+ reaffirmed); rationale attached as scanned images · Zydus Lifesciences Ltd (filed with NSE) · Tier 1: company or exchange filing · 11 Sep 2026
  30. S39CRISIL Ratings rating rationale, Zydus Lifesciences Ltd, 27 Dec 2024 · CRISIL Ratings Ltd · Tier 2: rating agency or regulator · 27 Dec 2024
  31. S40NSE security-wise bhavcopy (sec_bhavdata_full), 11 Nov 2026: ZYDUSLIFE EQ close Rs 1,199.50 · NSE (nsearchives.nseindia.com) · Tier 1: company or exchange filing · 11 Nov 2026
  32. S41Clarification on receipt of USFDA warning letter for the Jarod injectables facility (intimation of 30 Aug 2024) · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 3 Sep 2024
  33. S45Completion of block acquisition of 85.6% of Amplitude Surgical · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 29 Jul 2025
  34. S46Update on acquisition of Amplitude shares (tender offer and squeeze-out) · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 26 Oct 2025
  35. S47Closing of acquisition of Agenus biologics manufacturing facilities (US) · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 15 Jan 2026
  36. S48Settlement agreement with Astellas on Myrbetriq (mirabegron) · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 12 Feb 2026
  37. S50Update: US FDA Priority Review for saroglitazar NDA in PBC, PDUFA date 27 Nov 2026 · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 27 May 2026
  38. S51Receipt of USFDA warning letter for the Baddi formulations facility · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 3 Jun 2026
  39. S52Completion of acquisition and merger of Assertio Holdings Inc. · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 16 Jun 2026
  40. S53Settlement with indirect reseller plaintiffs, US generic drug pricing antitrust litigation (US$5.9 mn) · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 5 Sep 2026
  41. S55Appointment of Walker Chandiok & Co LLP as statutory auditors (rotation, from the 32nd AGM) · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 4 Nov 2026
  42. S56Change in CFO: Nitin Parekh to Tushar Shroff (from 1 Sep 2025) · Zydus Lifesciences Ltd (exchange disclosure, company IR site) · Tier 1: company or exchange filing · 20 May 2025
  43. S57Press release: Sun Pharma reports Q4FY26 and FY26 results (peer filing) · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 22 May 2026
  44. S58Press release: Q4 FY26 and FY26 results (peer filing) · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 13 May 2026
  45. S59Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (peer filing) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 12 May 2026
Changes to this page (v2 · 17 Nov 2026)
  1. v2 · 17 Nov 2026Reworded the margin caption so it names the company (no numbers changed). (editorial update, Q2 FY27)
  2. v1 · 12 Nov 2026First version. (first version)

Numbers come only from tier 1 and tier 2 sources. Read how we research.

Disclaimer

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.

Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.

Read the full disclaimer

Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.

All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.

Statements by company management are reported as statements, with their date and source; they are not our forecasts.